Managementva
Mr. Reisenauer, who joined Assertio’s Board in January 2025 and was appointed Chief Executive Officer in October 2025, has more than 30 years of experience successfully commercializing and launching products in the oncology space.
He previously served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., where he grew sales to nearly $5 billion while overseeing Marketing, Sales, Policy and Government Affairs, and Market Access for Oncology, Specialty, and Hospital products. Earlier at Astellas, he built the U.S. Oncology Commercial Franchise. Before that, he was Senior Vice President and Chief Commercial Officer at Micromet, Inc. (acquired by Amgen), leading commercial launch and pipeline development, and held senior roles at Abbott Laboratories, where he led global commercialization, licensing, and R&D strategy for oncology products and co-chaired the Oncology Therapeutic Executive Committee.
Mr. Reisenauer has served as a member of the Commercial Launch and Medical Affairs Advisory Board of Autolus Therapeutics since 2024 and previously served as a member of the board of directors of the PhRMA Trade Association from 2021 to 2024. Mr. Reisenauer holds a B.A. in Political Science from the University of Wisconsin.
Mr. Schwichtenberg was promoted to President and Chief Operating Officer on November 3, 2025. Reporting to him are the Commercial, Operations and Business Development functions within Assertio.
Since joining Assertio in 2018, he has held several leadership positions, including most recently as Chief Transformation Officer, and previously as Chief Commercial Officer and Chief Financial Officer. In these prior roles, Paul has driven operational and commercial execution while keeping the Company’s focus on financial discipline and profitability.
Before joining Assertio he served in the position of Director, Pricing and Planning at AbbVie, where he led the US Commercial Pricing Team of 63 professionals responsible for commercial, institutional and government contracting, government price reporting, financial reporting, and financial planning.
Prior to this, he was a Controller for Radio Flyer, Inc., and Takeda Pharmaceuticals, where he executed numerous enhancements to reporting technology to identify margin opportunities as well as integrated acquisitions across the consumer and pharmaceutical space.
Prior to entering the pharmaceutical industry, he was a senior auditor at Wolf & Company LLP. Mr. Schwichtenberg holds a bachelor’s degree in business administration from Roosevelt University and is a certified public accountant (CPA).
Dr. Franklin has served as Senior Vice President, Medical, of Assertio since March 2023. He oversees Assertio’s medical and clinical scientific leadership for development programs, product assessments and life cycle management.
Dr. Franklin was previously Chief Medical Officer at Finch Therapeutics, a microbiome-based biotechnology firm applying new technologies to the treatment of immuno-oncology, IBD and autism spectrum disorder. He was previously Chief Medical Officer of Salix Pharmaceuticals, a $2 billion division of Bausch Healthcare Corporation with a focus on gastrointestinal medicine, where he shaped and executed clinical, regulatory and medical affairs strategies for a suite of GI-related assets with a focus on lifecycle management. He previously held senior roles at Icon Bioscience, Oceana Therapeutics, The Medicines Company, Esprit Pharmaceuticals and Odyssey Pharmaceuticals.
Dr. Franklin holds a Bachelor of Applied Science, Pre-Medical Studies, from Lehigh University, and a Doctor of Medicine from Drexel University College Medicine. He completed his medical residency in general surgery at Long Island Jewish Medical Center, followed by a fellowship in lapro-endoscopy and minimally invasive surgery at Massachusetts General Hospital, Harvard Medical School. He completed a Master of Business Administration degree at LaSalle University.
Mr. Patel has served as Executive Vice President, Chief Financial Officer of Assertio since November 2023. Mr. Patel joined Assertio as Vice President, Controller in July 2019 with responsibility for all accounting policies and practices, internal controls, income taxes and reporting. In March of 2021, he was promoted to Senior Vice President, Chief Accounting Officer.
Most recently he served in the position of Director, Technical Accounting & Accounting Policy at US Foods, where he oversaw implementation of company-wide accounting policies and helped lead acquisition financial due diligence, with a focus on quality of earnings review and accounting integration activities. Prior to this, he spent 11 years with Ernst & Young holding multiple positions of increasing responsibility in its Assurance practice leading financial statement audits of strategic key clients.
Mr. Patel holds a bachelor’s degree in finance from the University of Illinois, a master’s degree in accounting from the University of Virginia and is a certified public accountant (CPA).
Mr. Schlessinger has served as Executive Vice President, General Counsel of Assertio since July 2021. Mr. Schlessinger joined Assertio as Senior Corporate Counsel in May 2020 and more recently served as Vice President, Legal, overseeing SEC reporting, corporate governance, due diligence and new business development, capital markets and licensing transactions, litigation, intellectual property, and compliance.
Most recently he served in the position of Corporate Partner for Dentons, LLP where he advised public and privately held clients in mergers and acquisitions, buyouts and recapitalizations, and securities transactions. In this role, he had significant transactional experience representing private equity and other clients in acquisitions and divestitures in regulated industries, with a specialty in healthcare.
Prior to this, he was a Corporate Associate at McDermott Will & Emery LLP, where he focused on pharmaceutical monetization agreements, private equity transactions, leveraged buyouts, mergers and acquisitions, divestitures, and reorganizations.
Mr. Schlessinger holds a bachelor’s degree in mathematics from the Pomona College and a juris doctorate from the University of Illinois.
Ms. Fox has served as Vice President, Commercial Strategy and Operations since November 2025. Previously, she served as Vice President, Business Development and Commercial Analytics since December 2021 and was responsible for Assertio’s business development strategy and planning and commercial analytics. Ms. Fox joined Assertio as Director of Market Research & Forecasting in May 2018 and previously held the progressive roles of Director, Revenue and Executive Director, Trade and Distribution.
Most recently she served in the position of Director, Business Development for Kastle Therapeutics, where she developed product forecasts and valuation models for potential product and company acquisitions and provided strategic and analytical support for a commercialized ultra-orphan product.
Prior to this, she held several successive roles at ZS Associates, a management consulting and analytics firm, lastly as Business Consulting Manager, where she resolved strategic sales and marketing issues for pharmaceutical companies through analytical modeling and qualitative research approaches.
Ms. Fox holds a bachelor’s degree in mathematics, psychology, and violin performance from the University of Notre Dame and a master’s degree in quantitative methods of psychology from Arizona State University.